You have 9 free searches left this month | to do more

tremelimumab

Tremelimumab is a drug used to treat Colorectal Cancer, Bladder Cancer, Breast Cancer, and other conditions. Tremelimumab is being actively studied in 71 studies and prior, has been studied in 21.

Top SponsorsTop SitesTop Investigators
AstraZenecaResearch SiteCatherine Shu
Canadian Cancer Trials GroupMemorial Sloan Kettering Cancer CenterMichele Maio
Memorial Sloan Kettering Cancer CenterJuravinski Cancer Centre at Hamilton Health SciencesA.J.M. van den Eertwegh
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
D
Suspended
  • Mesothelioma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-03-30
Mar 30, 2021
M
Completed
  • Metastatic Breast Cancer
  • Brain radiotherapy or Stereotactic Radiosurgery
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-07-15
Jul 15, 2021
B
Active, not recruiting
  • Mesothelioma
  • Houston, Texas
    Baylor St Lukes
2021-09-24
Sep 24, 2021
D
Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • (no location specified)
2021-08-27
Aug 27, 2021
P
Recruiting
  • Cancer
  • Rare Disease
  • Greenville, South Carolina
    Greenville Health System Cancer Institute
2021-09-30
Sep 30, 2021
F
Active, not recruiting
  • Metastatic Melanoma
  • Boston, Massachusetts
  • +1 more
2021-09-14
Sep 14, 2021
G
Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
2021-05-06
May 6, 2021
A
Active, not recruiting
  • Metastatic
  • +4 more
  • Radiotherapy
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
2021-10-12
Oct 12, 2021
M
Recruiting
  • Hepatocellular Carcinoma
  • Biliary Tract Cancer
  • Tremelimumab
  • +2 more
  • Boston, Massachusetts
  • +1 more
2021-04-22
Apr 22, 2021
C
Not yet recruiting
  • Nonsmall Cell Lung Cancer
  • New York, New York
    Columbia University
2021-04-14
Apr 14, 2021
S
Terminated
  • Primary Peritoneal Carcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2021-04-09
Apr 9, 2021
I
Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Tremelimumab
  • +3 more
  • Hanover, Germany
  • +1 more
2021-02-11
Feb 11, 2021
A
Active, not recruiting
  • Cholangiocarcinoma
  • +3 more
  • Durvalumab
  • +3 more
  • Hannover, Germany
    Medizinische Hochschule Hannover, Klinik für Gastroenterologie,
2021-10-14
Oct 14, 2021
S
Not yet recruiting
  • Metastatic or Locally Advanced NSCLC
  • Ramat Gan, Israel
    Sheba Medical Centre
2021-08-10
Aug 10, 2021
M
Completed
  • Renal Cell Carcinoma
  • Kidney Cancer
  • Minneapolis, Minnesota
  • +1 more
2020-12-21
Dec 21, 2020
D
Recruiting
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
  • +1 more
2021-08-30
Aug 30, 2021
N
Suspended
  • Heptocellular Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-09-16
Sep 16, 2021
T
Recruiting
  • Urothelial Carcinoma
  • Tremelimumab
  • +2 more
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek Ziekenhuis
2021-03-15
Mar 15, 2021
G
Completed
  • Neoplasms
  • Boston, Massachusetts
  • +7 more
2021-10-04
Oct 4, 2021
B
Recruiting
  • Pancreatic Cancer Non-resectable
  • Durvalumab 50 MG/ML
  • +3 more
  • Leuven, Vlaams-Brabant, Belgium
    University Hospitals KU Leuven
2020-11-03
Nov 3, 2020
L
Completed
  • Breast Cancer
  • +4 more
  • New Haven, Connecticut
  • +5 more
2021-07-13
Jul 13, 2021
U
Terminated
  • Muscle-invasive Bladder Cancer
  • Durvalumab (Imfinzi)
  • Tremelimumab
  • Berne, Switzerland
    Departement of Medical Oncology, University Hospital Berne
2020-06-16
Jun 16, 2020
C
Active, not recruiting
  • Solid Malignancies
  • Calgary, Alberta, Canada
  • +6 more
2021-02-11
Feb 11, 2021
F
Terminated
  • Germ Cell Tumor
  • Milano, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori
2021-05-12
May 12, 2021
M
Recruiting
  • Urothelial Carcinoma
  • Tremelimumab
  • Washington, District of Columbia
  • +6 more
2021-08-11
Aug 11, 2021